Anti-OX40 Antibody Combined with HBc VLPs Delays Tumor Growth in a Mouse Colon Cancer Model
CONCLUSION: Combination therapy of anti-hOX40 and HBc VLPs provides synergistic antitumor activity in colon cancer-bearing mice, which may represent a potential design strategy for cancer immunotherapy.PMID:38582981 | DOI:10.3967/bes2024.019
Source: Biomedical and Environmental Sciences : BES - Category: Biomedical Science Authors: Jia Jia Liu Qiu Dong Su Yao Yi Li Ping Shen Sheng Li Bi Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Environmental Health | Hepatitis | Hepatitis B | Immunotherapy | Study